Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314122 | 0.81 | L3MBTL1 (0.40) | ALDH1A1LMNA | |
| SCHEMBL375759 | 0.81 | ALDH1A1 (0.71) | ALDH1A1KMT2AMAPTMEN1LMNA | |
| SCHEMBL3352155 | 0.81 | ALDH1A1 (0.43) | ALDH1A1KMT2AMAPTMEN1LMNA | |
| SCHEMBL3314196 | 0.79 | GAK (0.39) | ALDH1A1 | |
| SCHEMBL18763996 | 0.78 | ALDH1A1 (0.60) | ALDH1A1KMT2AMAPTMEN1LMNA | |
| SCHEMBL17197310 | 0.78 | ALDH1A1 (0.60) | ALDH1A1KMT2AMAPTMEN1LMNA | |
| SCHEMBL30900295 | 0.75 | SIRT6 (0.55) | ALDH1A1KMT2AMAPTMEN1LMNA | |
| SCHEMBL4802163 | 0.75 | GHSR (0.52) | ALDH1A1KMT2AMAPTLMNASIRT6 | |
| SCHEMBL4802144 | 0.75 | GHSR (0.52) | ALDH1A1KMT2AMAPTLMNASIRT6 | |
| SCHEMBL3314034 | 0.74 | SIRT6 (0.55) | ALDH1A1MAPTLMNASIRT6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | ALDH1A1 649/4885KMT2A 3784/4885MAPT 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.